The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia
The DOI matches its Crossref record.
Abstract
To gain insight of the underlying mechanisms of astroglial response to Alzheimer’s disease (AD), the level of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) from controls and AD subjects were immunochemically determined, and the correlation between that level and dementia severity of AD patients was evaluated. Means and SD of CSF levels of GFAP for the young control group (from 1 to 25 years, mean ± SD 14.2 ± 5.0, n = 13) adult control (from 26 to 55 years, 41.6 ± 10.1, n = 9) and senescent control (older than 56 years, 65.4 ± 8.0, n = 8) were 2.96 ± 1.04, 2.80 ± 1.46 and 3.99 ± 1.55 ng/ml, respectively, and the CSF level of GFAP was not dependent on age (ANOVA, p = 0.17). While that of the AD patient group (n = 27, 70.8 ± 8.0 years) was 8.96 ± 7.80 ng/ml, significantly higher than that of both the all-control (3.19 ± 1.39 ng/ml, t test, p < 0.001) and age-matched senescent (3.99 ± 1.55 ng/ml, t test, p < 0.005) control groups. The receiver-operator characteristic (ROC) curve revealed that the GFAP concentration at 5 ng/ml in CSF could serve as a cutoff value. The CSF level of GFAP in the moderately to severely demented patients (MMSE ≤ 17, 13.2 ± 9.10 ng/ml, n = 9) was approximately by two-fold higher than that of the mildly to moderately demented patients (MMSE ≧ 18, 6.85 ± 5.76 ng/ml, n = 18; ANOVA, p < 0.05). These findings together with our previous report on an increase in the CSF level of apolipoprotein E suggest that degeneration and stimulation of astrocytes takes place concurrently in the AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258
Microglia and Astrocyte Function and Communication: What Do We Know in Humans?
Garland, E. F., Hartnell, I. J., & Boche, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824888 · Cited by 165
“It is detectible in the CSF of AD patients and is correlated with the cognitive score assessed with the MMSE (Fukuyama et al., 2001).”
Ishiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156
“Fukuyama et al. (2001) also described a gradual increase in the levels of GFAP in the CSF with AD progression, although a strong correlation was not observed between the levels of GFAP and MMSE scores.”
BackgroundProteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain
Korolainen, M. A., Auriola, S., Nyman, T. A., Alafuzoff, I., & Pirttilä, T. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.021 · Cited by 133
Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis
Bellaver, B., Ferrari-Souza, J. P., Uglione da Ros, L., Carter, S. F., Rodriguez-Vieitez, E., Nordberg, A., Pellerin, L., Rosa-Neto, P., Leffa, D. T., & Zimmer, E. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012109 · Cited by 123
“In addition, it has been shown that GFAP levels in the CSF negatively correlate with Mini-Mental State Examination scores in patients with AD.(22,25) The remarkable homogeneity among studies and the high effect size observed in this meta-analysis support the inclusion of CSF GFAP in AD clinical studies.”
ResultZhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86
Inflammation as common link to progressive neurological diseases
Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03628-8 · Cited by 60
Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Santos, F., Cabreira, V., Rocha, S., & Massano, J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221141651 · Cited by 24
“Amyloid plaques are surrounded by reactive astrocytes, even at early stages of AD.107-109 This reactive state leads to an increased expression of its intermediate filament, GFAP, a marker of astrogliosis,110 in AD brain tissue and CSF.111,112 Although GFAP figures as a promising biomarker to distinguish between AD and…”
Background
Metadata
- Authors
- Fukuyama, R., Izumoto, T., & Fushiki, S.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 46
- Issue
- 1
- Pages
- 35-38
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2013999013
- Cited by
- 100
- References
- 0
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.